Article Information
History
- June 2, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jorge da Rocha1,2,‡,*,†,
- Houcemeddine Othman1,‡,
- Caroline T. Tiemessen3,
- Gerrit Botha4,‡,
- Michèle Ramsay1,2,‡,
- Collen Masimirembwa1,
- Clement Adebamowo5,6,‡,
- Ananyo Choudhury1,‡,
- Jean-Tristan Brandenburg1,‡,
- Mogomotsi Matshaba8,9,‡,
- Gustave Simo7,‡,
- Francisco-Javier Gamo10,
- Scott Hazelhurst11,1,‡,
- as members of the H3Africa Consortium‡
- 1Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 2Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 3Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg South Africa
- 4Computational Biology Division and H3ABioNet, Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
- 5Institute for Human Virology, Abuja, Nigeria
- 6Institute of Human Virology and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD
- 7Molecular Parasitology and Entomology Unit, Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon
- 8Botswana-Baylor Children’s Clinical Center of Excellence, Gaborone, Botswana
- 9Baylor College of Medicine, Houston, United States
- 10Global Health, GlaxoSmithKline R&D, Madrid, Spain
- 11School of Electrical & Information Engineering, University of the Witwatersrand, Johannesburg, South Africa
- ↵† Corresponding author; email: jdarocha1{at}gmail.com
Posted June 02, 2020.
G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19
